Cracking The Code: Understanding Analyst Reviews For Caribou Biosciences
During the last three months, 5 analysts shared their evaluations of Caribou Biosciences (NASDAQ:CRBU), revealing diverse outlooks from…
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Structure Therapeutics (NASDAQ:GPCR) stock moved upwards by 71.0% to $58.47 during Monday’s regular session. The market value…
Attention Biotech Investors – Stocks To Watch
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences, and Corbus Pharmaceuticals with key 2024 data readouts and trials.
Expert Ratings For Caribou Biosciences
Ratings for Caribou Biosciences (NASDAQ:CRBU) were provided by 4 analysts in the past three months, showcasing a mix…
Caribou Biosciences To Present Initial Dose Expansion Data From CB-010 ANTLER Phase 1 Trial In r/r B-NHL At The 2024 American Society Of Clinical Oncology Annual Meeting
Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of
Caribou Biosciences Announces Oral Presentation On In Vivo Cas12a chRDNA Genome Editing At The 27th Annual Meeting Of ASGCT
Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on the efficient use of Cas12a chRDNA genome-editing technology for in vivo
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday.
Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus
-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety and efficacy
Caribou Biosciences Named Tim Kelly as Chief Technology Officer
Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tim Kelly to the newly created position of chief technology officer.
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday.